ArticleJournal of gastrointestinal oncology2020
Correlation between Claudin-18 expression and clinicopathological features and prognosis in patients with gastric cancer.
Article in Journal of gastrointestinal oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Prognostic significance of Claudin18.2 expression in patients with gastric cancer.Scientific reports · 2025Pooled it
- Clinicopathological significance and prognostic values of claudin18.2 expression in solid tumors: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Claudin18.2 promote gastric cancer proliferation by activating MCM2/5.Scientific reports · 2026Article
- Claudin 18.2 Expression in Gastric Adenocarcinoma: Diagnostic Reproducibility and Clinicopathologic Associations in A Western Cohort.Oncology research · 2026Article
- Expression of Claudin18.2 in metastatic lesions in peritoneum of gastric cancer.Journal of gastrointestinal oncology · 2025Article
- A novel prognostic and therapeutic target biomarker based on complement-related gene signature in gastric cancer.Translational cancer research · 2023Article
- Expression patterns of claudins in cancer.Heliyon · 2023Review
- Article
- Prognostic importance of the preoperative New-Naples prognostic score for patients with gastric cancer.Cancer medicine · 2023Article
- Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer.Journal of cancer research and clinical oncology · 2022Review
- Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials.Tissue barriers · 2022Review
- Intestinal Barrier, Claudins and Mycotoxins.Toxins · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate the correlation between Claudin-18 expression and the clinicopathological features and prognosis of gastric cancer.
methodsA total of 63 patients who underwent gastric cancer surgery from December 2012 to June 2013 were recruited as the research participants. The clinicopathological data and prognostic information of the participants were collected, and expression levels of Claudin-18 in gastric cancer and adjacent tissues were detected by immunohistochemical (IHC) staining. The correlation between Claudin-18 expression and clinicopathological features of gastric cancer patients was analyzed. The Cox regression model was used to analyze the risk factors associated with the prognosis of gastric cancer patients.
resultsThe expression of Claudin-18 was positive in 35 (55.6%) of the participants' gastric cancer tissues, which was significantly lower than that in the adjacent tissues (51 tissues/81.0%), and the difference was statistically significant (P=0.002). In addition, the IHC staining score of Claudin-18 expression in gastric cancer tissues (1.49±1.69), was significantly lower than that in the adjacent tissues (4.61±1.81), and the difference was statistically significant (P=0.016), The incidence of nerve invasion in patients with low expression of Claudin-18 was significantly higher than that in patients with high expression of Claudin-18 (P=0.038). In addition, univariate Cox regression analysis showed that nerve invasion, Claudin-18 staining score, tumor size, and positive count of lymph nodes were risk factors associated with the survival of gastric cancer patients. Multivariate Cox regression analysis showed that Claudin-18 staining score and tumor size were independent risk factors associated with the survival of gastric cancer patients. The overall survival (OS) of patients with low Claudin-18 staining score or larger tumor size was significantly reduced.
conclusionsThe low expression of Claudin-18 was closely related to nerve invasion in gastric cancer, which indicated the poor clinical prognosis of gastric cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.